Cipla soars as its partner Sandoz gets USFDA’s nod for generic drug

30 Jul 2015 Evaluate

Cipla is currently trading at Rs. 705.35, up by 27.70 points or 4.09 % from its previous closing of Rs. 677.65 on the BSE.

The scrip opened at Rs. 682.20 and has touched a high and low of Rs. 707.40 and Rs. 682.20 respectively. So far 146824 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 752.45 on 10-Mar-2015 and a 52 week low of Rs. 430.35 on 08-Aug-2014.

Last one week high and low of the scrip stood at Rs. 688.50 and Rs. 663.80 respectively. The current market cap of the company is Rs. 56715.26 crore.

The promoters holding in the company stood at 36.79 % while Institutions and Non-Institutions held 34.30 % and 26.60 % respectively.

Cipla’s partner Sandoz has received approval from United States Food and Drug Administration (USFDA) to launch a generic version of Pulmicort respules (budesonide).

Sandoz’s budesonide inhalation suspension product is indicated for maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age. Budesonide inhalation suspension is not indicated for the relief of acute bronchospasm.

Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 170 countries. Its portfolio includes over 2000 products in 65 therapeutic categories with one quality standard globally.

Cipla Share Price

1496.65 5.25 (0.35%)
31-Dec-2025 09:29 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1724.00
Dr. Reddys Lab 1265.00
Cipla 1496.65
Zydus Lifesciences 907.20
Lupin 2097.15
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×